Stuart J Connolly on Muck Rack

Stuart J Connolly

Burlington
As seen in: Daily Mail, Irish Daily Mail, EP Europace, heart, JAMA (The Journal of the American Medical Association), The New England Journal of Medicine, Irish Examiner, The Lancet, AHA/ASA Journals, Annals of Internal Medicine and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Stuart J

Contact Stuart J, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Results of the COMPASS trial analysed using win ratio compared with conventional analytic approaches.

|
By John Eikelboom, William F McIntyre, William Mcintyre, Jacqueline Bosch, Richard P. Whitlock, Qilong Yi, Stuart J Connolly, Thomas Scheier, Ákos F. Pap, Stuart J. Pocock, Shrikant Bangdiwala, Eva Muehlhofer
| Canadian Journal of Cardiology Verified
Abstract Win ratio (WR) is a newer analytic approach for trials with composite endpoints that accounts for the relative importance of individual components. Our objective was to compare the results of the COMPASS trial analysed using WR compared with conventional statistical approaches.
Open in Who Shared Issue with article?

Oral Anticoagulation Use and Left Atrial Appendage Occlusion in LAAOS III

|
By Stuart J Connolly, Jeff S. Healey, Emilie P Belley-Cote, Kumar Balasubramanian
| AHA/ASA Journals
Stuart J. Connolly Correspondence to: Stuart J. Connolly, MD, 30 Birge St, Hamilton, Ontario, Canada L8L 0A6. Email E-mail Address: stuart.connolly@phri.ca https://orcid.org/0000-0002-7377-335X Population Health Research Institute, Hamilton Health Sciences, McMaster University, Ontario, Canada (S.J.C., J.S.H., E.P.B.-C., K. Balasubramanian, K. Brady, P.J.D., M.S., C.R., S.Y., R.P.W.).
Open in Who Shared Issue with article?

Andexanet alfa postmarking trial stopped early due to superior efficacy

|
By Richard Smith, Stuart J Connolly
| Healio Cardiology Verified
Source/Disclosures Disclosures: The ANNEXA-4 trial was funded by Portola Pharmaceuticals, now part of AstraZeneca. Connolly reports receiving consultant fees, lecture fees and institutional research grants from Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Janssen, Pfizer and Portola. We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
Open in Who Shared Issue with article?
See all 25 licensed articles (26 Total)
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified